Sinco Pharmaceuticals Holdings Limited provided earnings guidance for the year ended December 31, 2020. For the year, the company expected to record an increase in profit attributable to the owners of the Company for the Year, representing an increase of not less than 270.0% as compared with the corresponding period in 2019 (the audited consolidated net profit attributable to owners of the Company for the year ended 31 December 2019 amounted to approximately RMB 22.9 million). The Board believes that the aforementioned increase is mainly attributable to i) the increase in gross profit due to the increase in sales of the Company; ii) the improvement of profitability as a result of the completion of the Company's previous construction of sales channel; and iii) the effective control of operating costs.